Post-market Registry to Assess the Clinical Performance and Safety of the Passeo-18 Lux in Infrainguinal Arteries

Angioplasty, Balloon Clinical Trial

Official title:

A Prospective, Multi-centre, Sinlge Arm, Post-market Registry to Assess the Clinical Performance and Safety of the Passeo-18 Lux Paclitaxel Releasing Balloon Catheter in Infrainguinal Arteries

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05175703
• Other study ID #: AJIRB-DEV-DE4-17-478
• Status: Active, not recruiting
• Phase: N/A
• Start date: March 5, 2018
• Est. completion date: January 31, 2022

Study information

• Verified date: December 2021
• Source: Ajou University School of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of his study is to collect short term and long term clinical evaluation data of the Passeo-18 Lux Paclitaxel releasing balloon catheter, subject to patients who visit hospital from arteriosclerosis in the infrainguinal arteries in actual clinical environment.

Research institute for enrollment, and period; It is planned to enroll about 200 subjects in 9 domestic research institutes. It is expected to require about 12-18 months to enroll the subjects.

Subject follow-up schedule; Perform follow-up by phone call or clinical assessment at 1, 6, 12, and 24 months of the postoperative time point

Description:

This study is a prospective, multicenter, single arm, post-market registry subject to all the patient group with the relevant indications, where follow-up is performed in 1, 6, 12 (including angio follow up), and 24 month. The Passeo-18 Lux DCB including all the target patient group, is subject to every disease requiring revascularization in the infrainguinal arteries and is going to use the Passeo-18 Lux DCB.

The subject will receive percutaneous intervention using Passeo-18 Lux DCB according to the standard care guideline of this hospital. All complications and adverse events occurring during the operation will be recorded thoroughly. During the intervention, the number of lesions to be treated with Passeo-18 Lux will be determined carefully under judgment of the PI (When using more than one Passeo-18 Lux in a patient, maximum drug release recommended in the IFU should be considered.) The target lesion which is compose of one or several small lesions treatable with a balloon catheter is defined as a "treatment segment". The results of all the lesions treated with Passeo-18 Lux for the first time (regardless of which side limb) are going to be documented in eCRF, through which final results will be analyzed. All complications and adverse events from the intervention will be recorded thoroughly and reported to IRB according to the prescribed form.

Stent insertion into the lesion finishing treatment with drug coated balloon catheter will be determined by the study physician. For the subjects follow-up via phone call or clinical assessment will be conducted under below schedule. In this study the subjects who require stent insertion will not be classified as treatment failure. Before discharge of the subjects, medical prescription will follow the standard of care of this hospital, which will be documented. All the postoperative complications and adverse events will be recorded thoroughly and reported to IRB via suitable form. The subjects will be administered with proper anticoagulant, antiplatelet drug, and blood vessel dilator according to common and standard care guideline. The treatment follows the guideline described in IFU of Passeo-18 Lux DCB.

A subject does not have to participate in this study for treatment of the stenosed lower limb blood vessel. For example, there are a lot of devices available for treatment of the subject, including standard drug coated balloon, laser, and stent. The study physician will provide sufficient explanation on these alternative therapies for his/her understanding. Even though a subject decided not to participate in this study, it would not affect current and future treatment that he/she receives.

As the subjects of this study participate in in this study voluntarily according to their own will, they can discontinue the participation without any disadvantage or limitation at any time when they desire. They will not receive any disadvantage in later treatment from that. However the information collected during participation may be able to be used as it was anonymized. When a subject discontinued participation of study early, the participation should be terminated after completing preparation of eCRF as soon as possible. Also, The principal investigator regards a case as failure in follow-up of a subject up to for 24 months. In failing the follow-up, the principal investigator should record the failure of follow-up on the CRF.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 200
• Est. completion date: January 31, 2022
• Est. primary completion date: August 31, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

• Person over 19 years old who is recognized as an adult in the civil law

• Person willing to sign a subject written consent

• Patient having infrainguinal arterial lesion that is adequate to intravascular treatment using Passeo-18 Lux Paclitaxel releasing Balloon Catheter

• Peripheral arterial disease in 2-5 grade of Rutherford

• Patient without at least one of significant lesions (=50% of stenosis) in distal leaking artery. When there is at least one of opening blood vessels under the knee in treatment of arterial popliteal or at least one of opening cural vessel under the ankle in arterial treatment under the knee. Treatment of inflow arterial disease is allowed before the relevant treatment.)

Exclusion Criteria:

• Life expectancy = 1 year

• Patient who is currently under medication of an investigation drug or treatment by a device that did not reach the primary endpoints.

• Subject during pregnancy or having a plan of pregnancy during the study period

• A guide wire could not passed into the target lesion (Successful passage of guide wire means its movement into the distal part of target lesion without causing arterial dissection or perforation by the end of guidewire.)

• Acute thrombosis is accompanied

• Major amputation is planned There is medical history of bypass surgery on target vessel

Related Conditions & MeSH terms

• Angioplasty, Balloon
• Peripheral Arterial Disease

Intervention

Device:
• Passeo-18 Lux Paclitaxel releasing Balloon Catheter
collect short term and long term clinical evaluation data of the Passeo-18 Lux Paclitaxel releasing balloon catheter, subject to patients who visit hospital from arteriosclerosis in the infrainguinal arteries in actual clinical environment.

Locations

Country	Name	City	State
Korea, Republic of	Ajou University Hospital	Suwon	Kyunggi

Sponsors (1)

Lead Sponsor	Collaborator
Ajou University School of Medicine

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinical primary endpoints	No occurrence of Major Adverse Event (MAE); No death or lower limb amputation in the subject from the index procedure for 30 days	30 days
Primary	Clinical primary endpoints	No occurrence of Major Adverse Event (MAE); No target vessel revascularization (TVR) within 6 months from index procedure.	6 months
Primary	Functional primary endpoints	No target lesion revascularization (TLR) (a case showing at least 50% stenosis in visual inspection of target vessel in the patient with any recurred symptom) is needed clinically for 12 months after operation.	12 months
Secondary	TLR (Target Lesion Revascularzation) rate	ratio of TLR patients among full cohort within 6 ~ 24 months	6-24 months
Secondary	TVR rate	ratio of TVR patients among full cohort within 6 ~ 24 months	6-24 months
Secondary	Survival without amputation	Survival without amputation (survival without whole amputation including minor and major amputation) for 6, 12, and 24 months after operation	6-24 months
Secondary	device success	definition of device success : Successful guide, inflation, deflation, and withdrawal of the Passeo-18 Lux Paclitaxel releasing balloon catheter	during index procedure
Secondary	Technical success	definition of technical success : Finished vascular procedure successfully and achieved =50% residual stenosis rate when assessing under visual inspection immediately after operation	during index procedure
Secondary	Success in operation	definition of op : Defined it as the case that technical success and device success were achieved and no MAE occurred during the index procedure period.	during index procedure